Hostname: page-component-f554764f5-68cz6 Total loading time: 0 Render date: 2025-04-11T10:31:37.187Z Has data issue: false hasContentIssue false
  • English
  • Français

Approval and Withdrawal of New Antibiotics and other Antiinfectives in the U.S., 1980–2009

Published online by Cambridge University Press:  01 January 2021

Kevin Outterson ,
John H. Powers ,
Enrique Seoane-Vazquez ,
Rosa Rodriguez-Monguio  and
Aaron S. Kesselheim
Get access Rights & Permissions [Opens in a new window]

Extract

Antibiotic use triggers evolutionary and ecological responses from bacteria, leading to antibiotic resistance and harmful patient outcomes. Two complementary strategies support long-term antibiotic effectiveness: conservation of existing therapies and production of novel antibiotics. Conservation encompasses infection control, antibiotic stewardship, and other public health interventions to prevent infection, which reduce antibiotic demand. Production of new antibiotics allows physicians to replace existing drugs rendered less effective by resistance.

In recent years, physicians and policymakers have raised concerns about the pipeline for new antibiotics, pointing to a decline in the number of antibiotics approved since the 1980s. This trend has been attributed to high research and development costs, low reimbursement for antibiotics, and regulatory standards for review and approval. Professional societies and researchers around the world have called for renewed emphasis on antimicrobial stewardship, while also supporting antibiotic research and development through grants, changes to intellectual property laws to extend market exclusivity periods, and modification of premarket testing regulations to reduce antibiotic development time and expenses.

Type
Independent
Information
Journal of Law, Medicine & Ethics , Volume 41 , Issue 3 , Fall 2013 , pp. 688 - 696
Copyright
Copyright © American Society of Law, Medicine and Ethics 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Lipsitch, M. Samore, M. H., “Antimicrobial Use and Antimicrobial Resistance: A Population Perspective,” Emerging Infectious Disease 8, no. 4 (2002): 347–354; Klein, E. Smith, D. L. Laxminarayan, R., “Hospitalizations and Deaths Caused by Methicillin-Resistant Staphylococcus Aureus, United States, 1999–2005,” Emerging Infectious Disease 13, no. 12 (2007): 1840–1846; Baquero, F. Coque, T. M. de la Cruz, F., “Ecology and Evolution as Targets: The Need for Novel Eco-Evo Drugs and Strategies to Fight Antibiotic Resistance,” Antimicrobial Agents and Chemotherapy 55, no. 8 (2011): 3649–3660.Google Scholar
Kesselheim, A. S. Outterson, K., “Fighting Antibiotic Resistance: Marrying New Financial Incentives to Meeting Public Health Goals,” Health Affairs 29, no. 9 (2010): 1689–1696; Laxminarayan, R. Malani, A., “Extending the Cure: Policy Responses to the Growing Threat of Antibiotic Resistance,” Resources for the Future, 2007, available at <http://www.extendingthecure.org/report> (last visited July 26, 2013); Kesselheim, A. S. Outterson, K., “Improving Antibiotic Markets for Long Term Sustainability,” Yale Journal of Health Policy, Law and Ethics 11, no. 1 (2011): 101–167; Outterson, K. Samora, J. B. Keller-Cuda, K., “Will Longer Antimicrobial Patents Improve Global Public Health?” The Lancet Infectious Disease 7, no. 8 (2007): 559–566; So, A. D. Gupta, N. Brahmachari, S. K. Chopra, I. Munos, B. Nathan, C. Outterson, K. Paccaud, J. P. Payne, D. J. Peeling, R. W. Spigelman, M. Weigelt, J., “Towards New Business Models for R&D for Novel Antibiotics,” Drug Resistance Updates 14, no. 2 (2011): 88–94.CrossRefGoogle Scholar
See id. (Kesselheim and Outterson, 2010); id. (Laxminarayan, Malani, ); id. (Kesselheim, Outterson, , 2011); id. (Outterson, Samora, Keller-Cuda, ); id. (So, et al.); “Policy Statement on Antimicrobial Stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS),” Infection Control and Hospital Epidemiology 33, no. 4 (2012): 322–327 [hereinafter cited as Policy Statement].Google Scholar
See supra note 2.Google Scholar
ECDC/EMEA, Joint Technical Report: The Bacterial Challenge: Time to React – A Call to Narrow the Gap between Multidrug-Resistant Bacteria in the EU and the Development of New Antibacterial Agents (2009), available at <http://www.ema.europa.eu/docs/en_GB/document_library/Report/2009/11/WC500008770.pdf> (last visited July 29, 2013); Spellberg, B. Powers, J. H. Brass, E. P. Miller, L. G. Edwards, J. E. Jr., “Trends in Antimicrobial Drug Development: Implications for the Future,” Clinical Infectious Diseases 38, no. 9 (2004): 1279–1286; Infectious Diseases Society of America, Bad Bugs, No Drugs: As Antibiotic Discovery Stagnates … a Public Health Crisis Brews (2004), available at <http://www.idsociety.org/uploaded-Files/IDSA/Policy_and_Advocacy/Current_Topics_and_Issues/Antimicrobial_Resistance/10x20/Images/Bad%20Bugs%20no%20Drugs.pdf> (last visited July 29, 2013); Freire-Moran, L. Aronsson, B. Manz, C. Gyssens, I. C. So, A. D. Monnet, D. L. Cars, O., ECDC-EMA Working Group, “Critical Shortage of New Antibiotics in Development against Multidrug-Resistant Bacteria – Time to React Is Now,” Drug Resistance Updates 14, no. 2 (2011): 118–124; Swedish Presidency of the European Union, Innovative Incentives for Effective Antibacterials, Stockholm, Sweden, September 17, 2009, available at <http://www.lakemedelsverket.se/upload/nyheter/2009/Rapport%20fr%C3%A5n%20m%C3%B6tet.pdf> (last visited August 14, 2013); Projan, S. J., “Why Is Big Pharma Getting Out of Antibacterial Drug Discovery?” Current Opinion in Microbiology 6, no. 5 (2003): 427–430.Google Scholar
Id. (Projan); Munos, B., “Lessons from 60 Years of Pharmaceutical Innovation,” Nature Reviews Drug Discovery 8, no. 12 (2009): 959–968.CrossRefGoogle Scholar
See Policy Statement, supra note 3; Allerberger, F. Gareis, R. Jindrak, V. Struelens, M. J., “Antibiotic Stewardship Implementation in the EU: The Way Forward,” Expert Review of Anti-Infective Therapy 7, no. 10 (2009): 1175–1183.CrossRefGoogle Scholar
See ECDC/EMEA, supra note 5; Spellberg, et al., supra note 5; Infectious Diseases Society of America, supra note 5; Freire-Moran, et al., supra note 5; Swedish Presidency of the European Union, supra note 5.Google Scholar
See Outterson, K., “All Pain; No GAIN: Need for Prudent Antimicrobial Use Provisions to Complement the GAIN Act,” Alliance for the Prudent Use of Antibiotics (APUA) Clinical Newsletter 30, no. 1 (2012): 13–15.Google Scholar
Id.Google Scholar
See ECDC/EMEA, supra note 5; Freire-Moran et al., supra note 5; Swedish Presidency of the European Union, supra note 5; Kirby, T., “Europe to Boost Development of New Antimicrobial Drugs,” The Lancet 379, no. 9833 (2012): 2229-2230; Mossialos, E., Morel, C. M., Edwards, S., Berenson, J., Gemmill-Toyama, M., and Brogan, D., Policies and Incentive for Promoting Innovation in Antibiotic Research, 2010 World Health Organization, on behalf of the European Observatory on Health Systems and Policies, available at http://www.euro.who.int/__data/assets/ pdf_file/0011/120143/E94241.pdf> (last visited July 29, 2013).CrossRefGoogle Scholar
Outterson, K. Powers, J. H. Gould, I. M. Kesselheim, A. S., “Questions about the 10 x '20 Initiative,” Clinical Infectious Diseases 51, no. 6 (2010): 751–752.CrossRefGoogle Scholar
FDA, “Drugs@FDA,” available at <http://www.accessdata.fda.gov/scripts/cder/drugsatfda/> (last visited August 14, 2013).+(last+visited+August+14,+2013).>Google Scholar
WHO Collaborating Centre for Drug Statistics Methodology, “Structure and Princples,” available at <http://www.whocc.no/atc/> (last visited August 14, 2013).+(last+visited+August+14,+2013).>Google Scholar
Qureshi, Z. P. Seoane-Vazquez, E. Rodriguez-Monguio, R. Stevenson, K. B. Szeinbach, S. L., “Market Withdrawal of New Molecular Entities Approved in the United States from 1980 to 2009,” Pharmacoepidemiology and Drug Safety 20 (2011): 772–777.CrossRefGoogle Scholar
FDA/CDER/Office of Surveillance and Epidemiology, Levaquin (Levofloxacin) Oral Solution, 250 mg/10 ml BPCA Drug Use Review, July 10, 2008, available at <http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008–4399b1–12%20(Levaquin%20(levofloxacin)%20Use%20Review).pdf> (last visited July 29, 2013);Wysowski, D. K. Swartz, L., “Adverse Drug Event Surveillance and Drug Withdrawals in the United States, 1969–2002: The Importance of Reporting Suspected Reactions,” Archives of Internal Medicine 165, no. 12 (2005): 1363–1369; Olivier, P. Montastruc, J. L., “The Nature of the Scientific Evidence Leading to Drug Withdrawals for Pharmacovigilance Reasons in France,” Pharmacoepidemiology and Drug Safety 15, no. 11 (2006): 808–812; Lexchin, J., “Drug Withdrawals from the Canadian Market for Safety Reasons, 1963–2004,” CMAJ 172, no. 6 (2005): 765–767; Liu, H. H., “Safety Profile of the Fluoroquinolones: Focus on Levofloxacin,” Drug Safety 33, no. 5 (2010): 353–369; Issa, A. M. Phillips, K. A. Van Bebber, S. Nidamarthy, H. G. Lasser, K. E. Haas, J. S. Alldredge, B. K. Wachter, R. M. Bates, D. W., “Drug Withdrawals in the United States: A Systematic Review of the Evidence and Analysis of Trends,” Current Drug Safety 2, no. 3 (2007): 177–185; Bakke, O. M. Manocchia, M. de Abajo, F. Kaitin, K. I. Lasagna, L., “Drug Safety Discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: A Regulatory Perspective,” Clinical Pharmacology & Therapeutics 58, no. 1 (1995): 108–17.Google Scholar
US Government Accountability Office, FDA's Consideration of Evidence from Certain Clinical Trials, July 2010, available at <http://www.gao.gov/assets/310/308301.pdf> (last visited August 14, 2013); FDA, Guidance for Industry, Antibacterial Drug Products: Use of Noninferiority Trials to Support Approval, November 2010, available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070951.pdf> (last visited August 14, 2013). (last visited August 14, 2013); FDA, Guidance for Industry, Antibacterial Drug Products: Use of Noninferiority Trials to Support Approval, November 2010, available at (last visited August 14, 2013).' href=https://scholar.google.com/scholar?q=US+Government+Accountability+Office,+FDA's+Consideration+of+Evidence+from+Certain+Clinical+Trials,+July+2010,+available+at++(last+visited+August+14,+2013);+FDA,+Guidance+for+Industry,+Antibacterial+Drug+Products:+Use+of+Noninferiority+Trials+to+Support+Approval,+November+2010,+available+at++(last+visited+August+14,+2013).>Google Scholar
Pulcini, C. Bush, K. Craig, W. A. Frimodt-Moller, N. Grayson, M. Mouton, J. W. Turnidge, J. Harbarth, S. Gyssens, I. C., “ESCMID Study Group for Antibiotic Policies. Forgotten antibiotics: An inventory in Europe, the United States, Canada, and Australia,” Clinical Infectious Diseases 54, no. 2 (2012): 268–274.CrossRefGoogle Scholar
Hunt, M., Changing Patterns of Pharmaceutical Innovation (May 2002), National Institute for Health Care Management (NIHCM) Research and Educational Foundation, available at <http://www.nihcm.org/pdf/innovations.pdf> (last visited July 29, 2013).+(last+visited+July+29,+2013).>Google Scholar
See Outterson, , supra note 9.Google Scholar
See Projan, , supra note 5.Google Scholar
See Kesselheim, Outterson, (2010), supra note 2; Laxminarayan, Malani, , supra note 2; Kesselheim, Outterson, (2011), supra note 2; Outterson, Samora, Keller-Cuda, , supra note 2; So, et al., supra note 2; Love, J., Knowledge Ecology International, “Prizes to Stimulate Innovation,” available at <http://keionline.org/prizes> (last visited August 14, 2013).+(last+visited+August+14,+2013).>Google Scholar
See Qureshi, et al., supra note 15; see FDA/CDER/Office of Surveillance and Epidemiology, supra note 16; Wysowski, Swartz, , supra note 16; Olivier, Montastruc, , supra note 16; Lexchin, , supra note 16; Liu, , supra note 16; Issa, et al., supra note 16; Bakke, et al., supra note 16.Google Scholar
Breen, G. A. St. Peter, W. L., “Hypoprothrombinemia Associated with Cefmetazole,” Annals of Pharmacotherapy 31, no. 2 (1997): 180–184; Lipsky, J. J., “Antibiotic-Associated Hypoprothrombinemia,” Journal of Antimicrobial Chemotherapy 21 (1988): 281–300; Brown, R. B. Klar, J. Lemeshow, S. et al., “Enhanced Bleeding with Cefoxitin and Moxalactam,” Archives of Internal Medicine 146 (1986): 2159–2164.Google Scholar
Rubinstein, E., “History of Quinolones and Their Side Effects,” Chemotherapy 47, Supp. 3 (2001): 3–8.CrossRefGoogle Scholar